ProCol is a bovine mesenteric vein vascular bioprosthesis with numerous clinical publications and presentations showing good outcomes in hemodialysis access since 2000.(2,4,9,10,12,13) ProCol shows 57% and 54% secondary patency at 2 and 3 years, compared to 18% and 10% with ePTFE, in patients with a previously failed synthetic graft.(2)
Compared with ePTFE, ProCol has shown:
• 3.7 times lower relative risk of infection(2)
• 1.4 times lower relative risk of interventions(2)
• 1.7 times lower relative risk of thrombosis(2)
Compared with AVF, ProCol has shown:
• Comparable secondary patency to AVF(5)
Unique 1:1 Elastin to Collagen Ratio: Made from bovine mesenteric vein, ProCol has a high elastin to collagen ratio.
• Propagates pulsatile forward flow(3)
• Pulsatile and compliant(3)
For Redo Patients with Failed AV Graft Who Require a New Access(1-8)
• Hypercoagulable Patient History(3,4,8,13)
• Patients with High Risk of Infection(14)
• Patients Requiring Salvage of Existing Access(13)
• Graft Compliance at Anastomosis
Indications for Use: The ProCol Vascular Bioprosthesis is intended for the creation of a bridge graft for vascular access subsequent to at least one previously
failed prosthetic access graft.(14)
*Approved for sale in the United States only.
(1) Glickman MH, Lawson JH, Katzman HE, et al. Multicenter Results of Using a Mesenteric Vein Bioprosthesis (ProCol®) as a Conduit for Hemoaccess in Patients with Multiple ePTFE Grafts Placed in the Leg. 29th Global Vascular and Endovascular Issues, Techniques and Horizons. 2002.
(2) Katzman HE, Glickman MH, Schild AF, et al. Multicenter Evaluation of the Bovine Mesenteric Vein Bioprosthesis for Hemodialysis Access in Patients with an Earlier Failed Prosthetic Graft. J Am Coll Surg 2005; 201:223-230.
(3) Katzman HE. Bioprostheses for Hemodialysis Access and Clinical Applications of the ProCol® Graft. Presented at VEITH SYMPOSIUM Nov 2007; New York, NY.
(4) Glickman MH, Lawson JH, Katzman HE, et al. Challenges of hemodialysis access for high risk patients: Impact of mesenteric vein bioprosthetic graft. J Vasc Access 2003; 4:73-80.
(5) Gensler TW, Stout CL, Glickman MH. Grafts are Superior to Basilic Vein Transposition Arteriovenous Fistulae. Presented at VEITH SYMPOSIUM Nov 2008; New York, NY.
(6) Glickman MH, Katzman HE, Lawson JH. To Thigh Or Not To Thigh, Should a Prosthetic Graft Be Placed?. In: Henry ML, Ed. Vascular Access for Hemodialysis-IX. Los Angeles CA: Bonus Books, Inc.; 2005; 219-228.
(7) Bernik TR. ProCol® Mesenteric Vein Graft for Difficult AV Access. Presented at VEITH SYMPOSIUM 2005; New York, NY.
(8) Gray JL, O’Shea S, Ortel TL, et al. Evaluation and Management of Hypercoagulability in Vascular Access Patients. 29th Global Vascular and Endovascular Issues, Techniques and Horizons. 2002.
(9) Hatzibaloglou A, Velissaris I, Kaitzis D, et al. ProCol® vascular bioprosthesis for vascular access: Midterm results. J Vasc Access 2004; 5:16-18.
(10) Bacchini G, Del Vecchio L, Andrulli S, et al. Survival of Prosthetic Grafts of Different Materials after Impairment of a Native Arteriovenous Fistula in Hemodialysis Patients. ASAIO Journal 2001; 47:30-33.
(11) O’Shea SI, Lawson JH, Reddan D, et al. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 2003; 38:541-8.
(12) Tahami VB, Hakki H, Reber PU, et al. Polytetrafluoroethylene and bovine mesenterial vein grafts for hemodialysis access: a comparative study. J Vasc Access 2007; 8:17-20.
(13) Benedetto F, Carella G, Lentini S, et al. Use of bovine mesenteric vein in rescue vascular access surgery. J Vasc Access 2010; 11:112-114.
(14) ProCol Vascular Bioprosthesis Instructions for Use.